Original disclosure @ IFC website
Updated in EWS Jun 23, 2021
Disclosed by Bank May 25, 2021
Can you contribute information about this project?
Contact the EWS Team
According to the bank document, "The proposed IFC investment will primarily support Fosun Pharma’s manufacturing and distribution of COVID-19 related medical products, including the COVID-19 vaccine co-developed by Pfizer / BioNTech and COVID-19 testing kits and in China (the “Project”).
Fosun Pharma is headquartered in Shanghai, China. The Project involves capital expenditures associated with the expansion of cold-chain warehousing and distribution networks across China. "
"The Project cost is estimated to be up to US$420 million. IFC’s proposed investment is a straight senior loan of up to US$200 million with a tenor of up to seven years".
Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (“Fosun Pharma”, or the “Company”) is a manufacturer of pharmaceutical products and medical devices in China. Fosun Pharma has been listed on the Shanghai Stock Exchange since 1998 and Hong Kong Stock Exchange since 2012. The Sponsor is Fosun International Limited (“Fosun International”), which owns 36.6% of the Company while 63.4% is held by public shareholders.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||Fosun International Limited||Parent Company||-|
|-||-||-||-||Shanghai Fosun Pharmaceutical (Group) Co. Ltd.||Undisclosed||-|
1/ The Project Contact
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Contact: Mr. Zhang Xiang
Title: Finance Manager
Phone number: +86-21-33987000
Address: Building A, No. 1289 Yishan Road, Shanghai, China
2/ The IFC Contact
General IFC Inquiries
2121 Pennsylvania Avenue, NW
Washington DC 20433
3/ Local Access for Project Documentation
Environmental documents will be made accessible to locally affected communities.
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org